

Antiproliferative activity of a new quinone-copper(II) complex and a related naphthoquinone derivative.

Nathália Florencia B. Azeredo^{*1,2}, Christiane Fernandes¹, Adolfo Horn Jr¹, Pio Colepicolo², Ana Maria da C. Ferreira², Jackson A. L. Resende³, e Chaquip Daher Netto⁴.

¹LCQUI / UENF, Campos dos Goytacazes, Brazil; ²IQ / USP, São Paulo, Brazil. ³UFF, Niterói, Brazil; ⁴UFRJ, Macaé, Brazil;

*e-mail: nflorencia@usp.br

Naturally occurring quinones and their synthetic analogs are an important source of antineoplastic products, and some of these compounds have been used in clinic as chemotherapeutic agents¹. Lapachol is an example of quinone which occurs in the wood of several species of the *Bignoniaceae* family and it has been commercialized in Brazil as an antitumor drug since the 1970's². In this sense, we describe here the synthesis, characterization and evaluation of antiproliferative activity against two human uterine sarcoma tumor cells (MES-SA and analogous resistant MES-SA/Dx5) of a new copper(II) complex and a related compound, both naphthoquinone derivative. The new copper(II) complex [Cu(HBPA)(L)]Cl (1), [where HBPA is (2-hydroxybenzyl-2-pyridylmethyl)amine], was obtained by the reaction between the precursor Cu(HBPA)Cl₂³ and the quinone-stilbene (L). A related *o*-furan compound (Figure 1) was also obtained, through the catalyzed cyclization reaction by CuCl₂, and it was characterized by X-rays diffraction and electronic spectroscopy. Complex (1) was characterized by IR, UV/Vis spectroscopy, melting point, elemental analysis, X-rays diffraction, condutivimetry, and electrochemical measurements (CV), ESI(+)-MS, and EPR. Results obtained by MTT assays revealed that the copper(II) complex (1) is less active against the tested sarcoma cells, however the *o*-furan derivative presents antitumor activity three and ten times higher than the current medicine doxorubicin for MES-SA and MES-SA/Dx5, respectively.




Fig. 1. X-ray structures obtained for the copper(II) complex (left) and for the *o*-furan (right).

1. Almeida, J.C.; Paixao, D.A.; Marzano, I.M.; Ellena, J.; Pivatto, M.; Lopes, N.P.; Ferreira, A.M.D.C.; Pereira-Maia, E.C.; Guillard, S.; Guerra, W. *Polyhedron*, **2015**, 89, p. 1-8.
2. De Moraes, P.; Gaspar, F.; Borges, R.; Netto, C.D.; Leão, R.; Nájera, C.; Costa, P. *Synthesis (Stuttgart)*, **2015**, 47, 3505-3512.
3. Borges, L.J.H.; Bull, E.S.; Fernandes, C.; Horn Jr, A.; Azeredo, N. F. B; Resende, J. A. L.C.; Carvalho, E.C. Q.; Jerdy, H.L.; Kanashiro, M.M. Manuscript accepted by *Eur J Med Chem*.

FAPERJ, FAPESP, CAPES, CEPID-REDOXOMA